Die Onkologie pp 535-562 | Cite as

Hochdosistherapie und Stammzelltransplantation

  • C. Scheffold
  • W. E. Berdel
  • J. Kienast

Zusammenfassung

In den 50 Jahern seit den ersten llinischen Transplantationseversuchen hat sich die hämatopoetische Stammzelltransplantation zu einem wichtigen Element der modernen Tumortherapie und der Behandlung nichtmaligner Stammzell- und Immundefekte sowie bestimmter hereditärer Stoffwechselerkrankungen entwickelt. Neue Indikationsgebiete werden erschlossen und Anwendungsgrenzen, bedingt durch Alter,Vorbehandlung und Komorbidität der Patienten, verschieben sich. Möglich wurde dieser Fortschritt durch eine Vielzahl paralleler Entwicklungen auf den Gebieten der Transplantationsimmunologie und Stammzellbiologie sowie der immunsuppressiven und supportiven Therapie.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Abruzzese E, Radford JE, Miller JS et al. (1999) Detection of abnormal pre-transplant clones in progenitor cells of patients who developed myelodysplasia after autologous transplantation. Blood 94: 18141819Google Scholar
  2. Adkins DR (1998) Anaphylactoid reaction in a normal donor given granulocyte colony- stimulating factor.] Clin Oncol 16: 812–813Google Scholar
  3. Afessa B, Litzow MR,Tefferi A (2001) Bronchiolitis obliterans and other late onset non-infectious pulmonary complications in hematopoietic stem cell transplantation. Bone Marrow Transplant 28: 425–434Google Scholar
  4. Akpek G, Zahurak ML, Piantadosi S, Margolis J, Doherty J, Davidson R, Vogelsang GB (2001) Development of a prognostic model for grading chronic graft-versus-host disease. Blood 97: 1219–1226PubMedGoogle Scholar
  5. Alison MR, Poulsom R,Jeffery R et al. (2000) Hepatocytes from non-hepatic adult stem cells. Nature 406: 257PubMedGoogle Scholar
  6. Anderlini P, Korbling M, Dale D et al. (1997) Allogeneic blood stem cell transplantation: considerations for donors. Blood 90: 903–908PubMedGoogle Scholar
  7. Anderlini P, Przepiorka D, Korbling M, Champlin R (1998) Blood stem cell procurement: donor safety issues. Bone Marrow Transplant 21 Suppl 3: 535–39Google Scholar
  8. Appelbaum FR (2001) Haematopoietic cell transplantation as immunotherapy. Nature 411: 385–389PubMedGoogle Scholar
  9. Aversa F, Tabilio A, Velardi A et al. (1998) Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med 339: 1186–1193PubMedGoogle Scholar
  10. Avigan D, Pirofski LA, Lazarus HM (2001) Vaccination against infectious dis- ease following hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 7: 171–183PubMedGoogle Scholar
  11. Bacigalupo A, Lamparelli T, Bruzzi P et al. (2001) Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors:2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo ( GITMO ). Blood 98: 2942–2947Google Scholar
  12. Bahceci E, Read EJ, Leitman S, Childs R, Dunbar C, Young NS, Barrett Ai (2000) CD34+ cell dose predicts relapse and survival after T-cell-depleted HLA-identical haematopoietic stem cell transplantation ( HSCT) for haematological malignancies. Br J Haematol 108: 408–414Google Scholar
  13. Barker JN, Davies SM, DeFor T, Ramsay NK, Weisdorf DJ, Wagner JE (2001) Survival after transplantation of unrelated donor umbilical cord blood is comparable to that of human leukocyte antigen-matched unrelated donor bone marrow: results of a matched-pair analysis. Blood 97: 2957–2961PubMedGoogle Scholar
  14. Barr RD, Whang-Peng J, Perry S (1975) Hemopoietic stem cells in human peripheral blood. Science 190: 284–285PubMedGoogle Scholar
  15. Barrett Ai, Mavroudis D,Tisdale J et al. (1998) T cell-depleted bone marrow transplantation and delayed T cell add-back to control acute GVHD and conserve a graft-versus-leukemia effect. Bone Marrow Transplant 21: 543–551Google Scholar
  16. Bearman SI, Appelbaum FR, Buckner CD, Petersen FB, Fisher LD, Clift RA, Thomas ED (1988) Regimen-related toxicity in patients undergoing bone marrow transplantation.) Clin Oncol 6: 1562–1568Google Scholar
  17. Bence-Bruckler I, Bredeson C, Atkins H et al. (1998) A randomized trial of granulocyte colony-stimulating factor (Neupogen) starting day 1 vs day 7 post-autologous stem cell transplantation. Bone Marrow Transplant 22: 965–969PubMedGoogle Scholar
  18. Benkerrou M,JaisJP, Leblond V et al. (1998) Anti-B-cell monoclonal antibody treatment of severe posttransplant B-lymphoproliferative disorder: prognostic factors and long-term outcome. Blood 92: 3137–3147Google Scholar
  19. Bensinger WI, Buckner CD (1999) Preparative regimens. In: Thomas ED, Blume KG, Forman SJH (eds) Hematopoietic cell transplantation. Blackwell Science, Malden, MA, pp 123–124Google Scholar
  20. Bensinger WI, Martin Pi, Storer B et al. (2001) Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med 344: 175–181PubMedGoogle Scholar
  21. Betriebsverordnungen für pharmazeutische Unternehmer (PharmBetrV) vom 8.3.1985 (BGBI.I S. 546),zuletzt geändert durch § 35 desTFG vom 1.7.1998 (BGBI.I S. 1752).Google Scholar
  22. Bhatia S, Louie AD, Bhatia R et al. (2001) Solid cancers after bone marrow transplantation.) Clin Oncol 19: 464–471Google Scholar
  23. Bjorkstrand B (2001) European Group for Blood and Marrow Transplantation Registry studies in multiple myeloma. Semin Hematol 38: 219–225PubMedGoogle Scholar
  24. Bjorkstrand B, Svensson H, Goldschmidt H et al. (2001) Alpha-interferon maintenance treatment is associated with improved survival after high-dose treatment and autologous stem cell transplantation in patients with multiple myeloma: a retrospective registry study from the European Group for Blood and Marrow Transplantation ( EBMT ). Bone Marrow Transplant 27: 511–515Google Scholar
  25. Bjornson CR, Rietze RL, Reynolds BA, Magli MC, Vescovi AL (1999) Turning brain into blood:a hematopoietic fate adopted by adult neural stem cells in vivo. Science 283: 534–537PubMedGoogle Scholar
  26. Blume KG, Thomas ED (2000) A review of autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant 6: 1–12PubMedGoogle Scholar
  27. Brazelton TR, Rossi FM, Keshet GI, Blau HM (2000) From marrow to brain: expression of neuronal phenotypes in adult mice. Science 290: 17751779Google Scholar
  28. Brossart P, Wirths S, Brugger W, Kanz L (2001) Dendritic cells in cancer vaccines. Exp Hematol 29: 1247–1255PubMedGoogle Scholar
  29. Brown RA, Adkins D, Goodnough LT et al. (1997) Factors that influence the collection and engraftment of allogeneic peripheral-blood stem cells in patients with hematologic malignancies. J Clin Oncol 15: 30673074Google Scholar
  30. Carella AM, Giralt S,Slavin S (2000) Low intensity regimens with allogeneic hematopoietic stem cell transplantation as treatment of hematologic neoplasia. Haematologica 85: 304–313Google Scholar
  31. Carreras E, Bertz H, Arcese W et al. (1998) Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: a prospective cohort study of the European Group for Blood and Marrow Transplantation. European Group for Blood and Marrow Transplantation Chronic Leukemia Working Party. Blood 92: 35993604Google Scholar
  32. Cassileth PA, Harrington DP, Appelbaum FR et al. (1998) Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med 339: 1649–1656PubMedGoogle Scholar
  33. Cavallaro AM, Lilleby K, Majolino I, Storb R, Appelbaum FR, Rowley SD, Bensinger WI (2000) Three to six year follow-up of normal donors who received recombinant human granulocyte colony-stimulating factor. Bone Marrow Transplant 25: 85–89PubMedGoogle Scholar
  34. Cavazzana-Calvo M, Hacein-Bey-Abina S (2001) Correction of genetic blood defects by gene transfer.Curr Opin Hematol 8: 360–367Google Scholar
  35. Champlin RE, Schmitz N, Horowitz MM et al. (2000) Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. IBMTR Histocompatibility and Stem Cell Sources Working Committee and the European Group for Blood and Marrow Transplantation ( EBMT ). Blood 95: 3702–3709Google Scholar
  36. Chen J, Law P, Ball ED (2000) Failure of engraftment. In: Ball ED, Lister J, Law PH (eds) Hematopoietic stem cell therapy. Churchill Livingstone, Philadelphia, PA, pp 512–530Google Scholar
  37. Cheson BD (2002) CHOP plus rituximab–balancing facts and opinion. N Engl J Med 346: 280–282PubMedGoogle Scholar
  38. Childs R, Chernoff A, Contentin N et al. (2000) Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 343: 750–758PubMedGoogle Scholar
  39. Civin CI, Gore SD (1993) Antigenic analysis of hematopoiesis: a review. J Hematother 2: 137–144PubMedGoogle Scholar
  40. Collins RH, Jr, Goldstein S, Giralt S et al. (2000) Donor leukocyte infusions in acute lymphocytic leukemia. Bone Marrow Transplant 26: 511516Google Scholar
  41. Collins RH, Jr, Shpilberg O, Drobyski WR et al. (1997) Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.) Clin Oncol 15: 433–444Google Scholar
  42. Confer DL,Stroncek DF (1998) Bone marrow and peripheral blood stem cell donors. In:Thomas ED, Blume KG, Forman JH (eds) Hematopoietic cell transplantation. Blackwell Science, Malden, MA, pp 421–430Google Scholar
  43. Copelan EA, Ceselski SK, Ezzone SA et al. (1997) Mobilization of peripheral-blood progenitor cells with high-dose etoposide and granulocyte colony-stimulating factor in patients with breast cancer, non-Hodgkin’s lymphoma,and Hodgkin’s disease.) Clin Oncol 15: 759–765Google Scholar
  44. Curtis RE, Rowlings PA, Deeg Hi et al. (1997) Solid cancers after bone marrow transplantation. N Engl J Med 336: 897–904PubMedGoogle Scholar
  45. Curtis RE,Travis LB,Rowlings PA et al. (1999) Risk oflymphoproliferative disorders after bone marrow transplantation:a multi-institutional study. Blood 94: 2208–2216Google Scholar
  46. Damiani D, Fanin R, Silvestri F et al. (1997) Randomized trial of autologous filgrastim-primed bone marrow transplantation versus filgrastimmobilized peripheral blood stem cell transplantation in lymphoma patients. Blood 90: 36–42PubMedGoogle Scholar
  47. Davies SM, Kollman C, Anasetti C et al. (2000) Engraftment and survival after unrelated-donor bone marrow transplantation: a report from the national marrow donor program. Blood 96: 4096–4102PubMedGoogle Scholar
  48. Deisseroth AB,Zu Z,Claxton D et al. (1994) Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML. Blood 83: 3068–3076Google Scholar
  49. DemirerT, Buckner CD, Storer B et al. (1997) Effect of different chemotherapy regimens on peripheral-blood stem-cell collections in patients with breast cancer receiving granulocyte colony-stimulating factor.J Clin Oncol 15: 684–690Google Scholar
  50. Deutsche Gesellschaft für Immungenetik, Kommission für Knochenmarktransplantation (1999) Empfehlungen der Deutschen Gesellschaft fürGoogle Scholar
  51. Immungenetik (DGI) für die Spende von Knochenmark- und hämatopoetischen Stammzellen freiwilliger nicht verwandter Spender. DGI Aktuell, Sonderausgabe 1–14Google Scholar
  52. DGTI (1998) Durchführung präparativer zellulärer Hämapheresen zur Gewinnung von Blutbestandteilkonzentraten. Empfehlungen zur Blutstammzellapherese der Deutschen Gesellschaft für Transfusionsmedizin und Immunhämatologie (DGTI). Infusionstherapie und Transfusionsmedizin 25: 325–335Google Scholar
  53. Dolken G (2001) Detection of minimal residual disease.Adv Cancer Res 82: 133–185Google Scholar
  54. Doroshow JH (1988) Pharmacological basis for high-dose chemotherapy. In:Thomas ED, Blume KG, Forman JH (eds) Hematopoietic cell transplantation. Blackwell Science, Malden, MA, pp 103–122Google Scholar
  55. Dreger P, Kloss M, Petersen B, Haferlach T, Loffler H, Loeffler M, Schmitz N (1995) Autologous progenitor cell transplantation: prior exposure to stem cell-toxic drugs determines yield and engraftment of peripheral blood progenitor cell but not of bone marrow grafts. Blood 86: 3970–3978PubMedGoogle Scholar
  56. Dreger P, Schmitz N (2001) Allogeneic transplantation of blood stem cells: coming of age? Ann Hematol 80: 127–136PubMedGoogle Scholar
  57. Duhrsen U, Villeval JL, Boyd J, Kannourakis G, Morstyn G, Metcalf D (1988) Effects of recombinant human granulocyte colony-stimulating factor on hematopoietic progenitor cells in cancer patients. Blood 72: 20742081Google Scholar
  58. Eglitis MA, Mezey E (1997) Hematopoietic cells differentiate into both microglia and macroglia in the brains of adult mice.Proc Natl Acad Sci U S A 94: 4080–4085Google Scholar
  59. Einsele H, Bertz H, Beyer J et al. (2001) Epidemiology and interventional treatment strategies of infectious complications after allogenic stem-cell transplantation. Dtsch Med Wochenschr 126: 1278–1284PubMedGoogle Scholar
  60. Einsele H, Kanz L (1999) Allogeneic transplantation of stem cells. Internist (Berl) 40: 1249–1256Google Scholar
  61. Europäische Kommission (1999) Die Regelung der Arzneimittel in der Europäischen Union. Bd 4. Leitfaden für die gute Herstellungspraxis. Humanarzneimittel und Tierarzneimittel. Europäische Kommission. Generaldirektion Ill. Industrie Arzneimittel und KosmetikaGoogle Scholar
  62. Falzetti F, Aversa F, Minelli O, Tabilio A (1999) Spontaneous rupture of spleen during peripheral blood stem-cell mobilisation in a healthy donor. Lancet 353: 555PubMedGoogle Scholar
  63. Fermand JP, Ravaud P, Chevret Set al. (1998) High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood 92: 3131–3136PubMedGoogle Scholar
  64. Ferrara LM, Levy R, Chao NJ (1999) Pathophysiologic mechanisms of acute graft-vs.-host disease. Biol Blood Marrow Transplant 5: 347–356PubMedGoogle Scholar
  65. Ferrari G, Cusella-De Angelis G, Coletta M, Paolucci E, Stornaiuolo A, Cossu G, Mavilio F (1998) Muscle regeneration by bone marrow-derived myogenic progenitors. Science 279: 1528–1530PubMedGoogle Scholar
  66. Flinn IW, Lazarus HM (2001) Monoclonal antibodies and autologous stem cell transplantation for lymphoma. Bone Marrow Transplant 27: 565–569PubMedGoogle Scholar
  67. Frei E Ill, Cucchi CA, Rosowsky A et al. (1985) Alkylating agent resistance: in vitro studies with human cell lines. Proc Natl Acad Sci U S A 82: 21582162Google Scholar
  68. Fu S, Liesveld J (2000) Mobilization of hematopoietic stem cells. Blood Rev 14: 205–218PubMedGoogle Scholar
  69. Gahrton G,Svensson H,Cavo M et aí. (2001) Progress in allogenic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983–93 and 1994–8 at European Group for Blood and Marrow Transplantation centres.BrJ Haematol 113: 209–216Google Scholar
  70. Gesetz über den Verkehr mit Arzneimitteln (Arzneimittelgesetz - AMG) vom 24.8.1976 (BGBl. I S. 2445), in der Neufassung durch Bekanntmachung vom 11.12.1998 (BGBI.I S. 3585)Google Scholar
  71. Gesetz über Medizinprodukte (Medizinproduktegesetz - MPG, Fußnote 1) vom 2. August 1994 (BGBl. I S. 1963), geändert durch das Erste Gesetz zur Änderung des Medizinproduktegesetzes (1. MPG-ÄndG) vom 6. August 1998 (BGBI.1 S. 2005 )Google Scholar
  72. Gesetz zur Regelung des Transfusionswesen (Transfusionsgesetz) vom 1.Juli 1998 (BGBI.I S. 1752).Gesetzestext and Begründung der Bundesregierung vom 13.01.1998 (BT Drcks.13/9594)Google Scholar
  73. Giralt S,Thall PF,Khouri I etal. (2001) Melphalan and purine analog-containing preparative regimens:reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood 97: 631–637Google Scholar
  74. Gisselbrecht C, Prentice HG, Bacigalupo A et al. (1994) Placebo-controlled phase III trial of lenograstim in bone-marrow transplantation. Lancet 343: 696–700PubMedGoogle Scholar
  75. Gluckman E (2001) Hematopoietic stem-cell transplants using umbilical-cord blood. N Engl J Med 344: 1860–1861PubMedGoogle Scholar
  76. Gluckman E, Broxmeyer HA, Auerbach AD et al. (1989) Hematopoietic reconstitution in a patient with Fanconi’s anemia by means of umbilical-cord blood from an HLA-identical sibling. N Engl J Med 321: 11741178Google Scholar
  77. Goker H, Haznedaroglu IC, Chao NJ (2001) Acute graft-vs.-host disease: pathobiology and management. Exp Hematol 29: 259–277PubMedGoogle Scholar
  78. Goldman JM (1994) A special report: bone marrow transplants using volunteer donors–recommendations and requirements for a standardized practice throughout the world -1994 update.The WMDA Executive Committee. Blood 84: 2833–2839PubMedGoogle Scholar
  79. Goldman JM, Druker BJ (2001) Chronic myeloid leukemia: current treatment options. Blood 98: 2039–2042PubMedGoogle Scholar
  80. Goldman JM,Schmitz N, Niethammer D,Gratwoh IA (1998) Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe in 1998. -Accreditation Sub-Committee of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 21: 1–7Google Scholar
  81. Goldschmidt H, Hegenbart U, Haas R, Hunstein W (1996) Mobilization of peripheral blood progenitor cells with high-dose cyclophosphamide (4 or 7 g/m2) and granulocyte colony-stimulating factor in patients with multiple myeloma. Bone Marrow Transplant 17: 691–697PubMedGoogle Scholar
  82. Gomez-Espuch J, Moraleda JM, Ortuno F et al. (2000) Mobilization of hematopoietic progenitor cells with paclitaxel (taxol) as a single chemotheraupetic agent, associated with rhG-CSF. Bone Marrow Transplant 25: 231–235PubMedGoogle Scholar
  83. Goulmy E (1997) Minor histocompatibility antigens:fromT cell recognition to peptide identification. Hum Immunol 54: 8–14PubMedGoogle Scholar
  84. Gratama JW, Keeney M, Sutherland DR (1999) Enumeration of CD34+ hematopoietic stem and progenitor cells. In: Robinson JP, Darzynkiewicz Z, Dean P et al. (eds) Current protocols in cytometry.John Wiley Sons, New York, pp 6.4.1–6. 4. 22Google Scholar
  85. Gratwohl A, Hermans J, Goldman JM et al. (1998) Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation.Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.Lancet 352: 1087 1092Google Scholar
  86. Gratwohl A, Passweg J, Baldomero H, Urbano-Ispizua A (2001) Hematopoietic stem cell transplantation activity in Europe 1999. Bone Marrow Transplant 27: 899–916PubMedGoogle Scholar
  87. Gribben JG, Freedman AS,Neuberg D et al. (1991) Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. N Engl J Med 325: 1525–1533PubMedGoogle Scholar
  88. Haioun C, Lepage E,GisselbrechtCet al. (2O00) Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin’s lymphoma:final analysis of the prospective LNH87–2 protocol–a groupe d’Etude des lymphomes de l’Adulte study. J Clin Oncol 18: 3025–3030Google Scholar
  89. Hartman AR,Williams SF, Dillon JJ (1998) Survival, disease-free survival and adverse effects of conditioning for allogeneic bone marrow transplantation with busulfan/cyclophosphamide vs. total body irradiation: a meta-analysis. Bone Marrow Transplant 22: 439–443Google Scholar
  90. Hasford J,Pfirrmann M,Hehlmann R et al. (1998) A new prognostic score for survival of patients with chronic myeloid leukemia treated with inter-feron alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group.J Natl Cancer Inst 90: 850–858Google Scholar
  91. Ho VT, Soiffer RJ (2001) The history and future ofT-cell depletion as graftversus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation. Blood 98: 3192–3204PubMedGoogle Scholar
  92. Ho VT, Weller E, Lee Si, Alyea EP, Antin JH, Soiffer RJ (2001) Prognostic factors for early severe pulmonary complications after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 7: 223–229PubMedGoogle Scholar
  93. Hoglund M, Smedmyr B, Bengtsson M,Totterman TH, Cour-Chabernaud V, Yver A, Simonsson B (1997) Mobilization of CD34+ cells by glycosylated and nonglycosylated G-CSF in healthy volunteers–a comparative study. Eur J Haematol 59: 177–183Google Scholar
  94. Holler E, Kolb HJ, Hiller E et al. (1989) Microangiopathy in patient s on cyclosporine prophylaxis who developed acute graft-versus-host disease after HLA-identical bone marrow transplantation. Blood 73: 2018–2024PubMedGoogle Scholar
  95. Horowitz MM, Gale RP, Sonde’ PM et al. (1990) Graft-versus-leukemia reactions after bone marrow transplantation. Blood 75: 555–562PubMedGoogle Scholar
  96. Horwitz EM, Prockop DJ, Fitzpatrick LA et al. (1999) Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta. Nat Med 5: 309–313PubMedGoogle Scholar
  97. Hurley CK, Wade JA, Oudshoorn M et al. (1999) Histocompatibility testing guidelines for hematopoietic stem cell transplantation using volunteer donors:report from The World Marrow Donor Association. Quality Assurance and Donor Registries Working Groups of the World Marrow Donor Association. Bone Marrow Transplant 24: 119–121Google Scholar
  98. Jackson KA, MiT,Goodell MA (1999) Hematopoietic potential of stem cells isolated from murine skeletal muscle. Proc Natl Acad Sci USA 96: 14482–14486Google Scholar
  99. Jantunen E, Mahlamaki E, Nousiainen T (2000) Feasibility and toxicity of high-dose chemotherapy supported by peripheral blood stem cell transplantation in elderly patients (?60 years) with non-Hodgkin’s lymphoma: comparison with patients 60 years treated within the same protocol. Bone Marrow Transplant 26: 737–741PubMedGoogle Scholar
  100. Joint Accreditation Committee of ISHAGE-Europe and EBMT (1998) Standards for blood and marrow progenitor cell processing, collection and transplantation, 5th edn.CourmayeurGoogle Scholar
  101. Jones RB, Matthes S, Dufton C (1995) Pharmacokinetics. In: Armitage JO, Karen H, Antman MH (eds) High-dose cancer therapy. Williams Wilkins, Baltimore, MA, pp 49–68Google Scholar
  102. Kanz L, Brugger W (1999) Mobilization and ex vivo manipulation of peripheral blood progenitor cells for support of high-dose cancertherapy.ln: Thomas E, Blume K, Forman SH (eds) Hematopoietic cell transplantation. Blackwell Science, Malden MA, pp 455–468Google Scholar
  103. Keil F, Haas OA, Fritsch G et al. (1997) Donor leukocyte infusion for leukemic relapse after allogeneic marrow transplantation: lack of residual donor hematopoiesis predicts aplasia. Blood 89: 3113–3137PubMedGoogle Scholar
  104. Koc ON, Gerson SL, Cooper BW et al. (2000) Randomized cross-over trial of progenitor-cell mobilization: high-dose cyclophosphamide plus granulocyte colony-stimulating factor ( G-CSF) versus granulocyte-macrophage colony-stimulating factor plus G-CSF. J Clin Oncol 18: 1824–1830Google Scholar
  105. Kocher AA, Schuster MD, Szabolcs MJ et al. (2001) Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. Nat Med 7: 430–436PubMedGoogle Scholar
  106. Kolb HJ,MittermullerJ,Clemm C et aí. (1990) Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 76: 2462–2465Google Scholar
  107. Kolb HJ,Schattenberg A,Goldman JM et al. (1995) Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood 86: 2041–2050Google Scholar
  108. Korbling M,Anderlini P (2001) Peripheral blood stem cell versus bone marrow allotransplantation: does the source of hematopoietic stem cells matter? Blood 98: 2900–2908Google Scholar
  109. Krause DS, Fackler MJ, Civin CI, May WS (1996) CD34: structure, biology, and clinical utility. Blood 87: 1–13PubMedGoogle Scholar
  110. Krause DS,Theise ND, Collector MI et al. (2001) Multi-organ, multi-lineage engraftment by a single bone marrow-derived stem cell. Cell 105: 369–377Google Scholar
  111. Kroger N, Renges H, Kruger W et al. (2000) A randomized comparison of once versus twice daily recombinant human granulocyte colony-stimulating factor (filgrastim) for stem cell mobilization in healthy donors for allogeneic transplantation. Br J Haematol 111: 761–765PubMedGoogle Scholar
  112. Kurnick NB, Montano A, Gerdes JC, Feder BH (1958) Preliminary observations on the treatment of postirradiation hematopoietic depression in man by the infusion of stored autogenous bone marrow. Ann Intern Med 49: 973–977PubMedGoogle Scholar
  113. Lane TA, Law P, Maruyama M et al. (1995) Harvesting and enrichment of hematopoietic progenitor cells mobilized into the peripheral blood of normal donors by granulocyte-macrophage colony-stimulating factor (GM-CSF) or G-CSF: potential role in allogeneic marrow transplantation. Blood 85: 275–282PubMedGoogle Scholar
  114. Laport GG, Fleming GF,Waggoner S,Zimmerman TM,Grinblatt DL, Williams SF (2001) A phase II trial of docetaxel for peripheral blood stem cell mobilization for patients with breast cancer and ovarian cancer. Bone Marrow Transplant 27: 677–681Google Scholar
  115. Laughlin MJ, Barker J, Bambach B et al. (2001) Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors. N Engl J Med 344: 1815–1822PubMedGoogle Scholar
  116. Law P (2000) Graft processing, storage, and infusion. In: Bal l ED, Lister J, Law PH (eds) Hematopoietic stem cell therapy. Churchill Livingstone, Philadelphia, PA, pp 312–321Google Scholar
  117. Lazarus HM, Loberiza FR Jr, Zhang MJ et al. (2001) Autotransplants for Hodgkin’s disease in first relapse or second remission: a report from the autologous blood and marrow transplant registry ( ABMTR ). Bone Marrow Transplant 27: 387–396Google Scholar
  118. Linch DC, Scarffe H, Proctor S et al. (1993) Randomised vehicle-controlled dose-finding study of glycosylated recombinant human granulocyte colony-stimulating factor after bone marrow transplantation. Bone Marrow Transplant 11: 307–311PubMedGoogle Scholar
  119. Ljungman P (1999) Immunization of transplant recipients. Bone Marrow Transplant 23: 635–636PubMedGoogle Scholar
  120. Lokhorst HM, Schattenberg A, Cornelissen JJ et al. (2000) Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome. J Clin Oncol 18: 3031–3037PubMedGoogle Scholar
  121. Mackinnon S, Papadopoulos EB, Carabasi MH et al. (1995) Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 86: 1261–1268PubMedGoogle Scholar
  122. Mangan KF (2000) Choice of conditioning regimens. In: Ball ED, Lister J, Law PH (eds) Hematopoietic stem cell therapy. Churchill Livingstone, Philadelphia, PA, pp 403–413Google Scholar
  123. Martino R, Romero P, Subira M et al. (1999) Comparison of the classic Glucksberg criteria and the IBMTR Severity Index for grading acute graft-versus-host disease following HLA-identical sibling stem cell transplantation. International Bone Marrow Transplant Registry. Bone Marrow Transplant 24: 283–287Google Scholar
  124. Mayani H,Lansdorp PM (1998) Biology of human umbilical cord blood-de- rived hematopoietic stem/progenitor cells. Stem Cells 16: 153–165Google Scholar
  125. McQuaker IG, Hunter AE, Pacey S, Haynes AP, Igbal A, Russell NH (1997) Low-dose filgrastim significantly enhances neutrophil recovery following autologous peripheral-blood stem-cell transplantation in patients with lymphoproliferative disorders: evidence for clinical and economic benefit.J Clin Oncol 15: 451–457Google Scholar
  126. McSweeney PA, Niederwieser D, Shizuru JA et al. (2001) Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus- tumor effects. Blood 97: 3390–3400PubMedGoogle Scholar
  127. Meldgaard Knudsen L, Jensen L, Gaarsdal E, Nikolaisen K, Johnsen HE (2000) A comparative study of sequential priming and mobilisation of progenitor cells with rhG-CSF alone and high-dose cyclophosphamide plus rhG-CSF. Bone Marrow Transplant 26: 717–722Google Scholar
  128. Metcalf D (1998) Mechanisms of human hematopoiesis. In: Thomas DE, Blume KG, Forman JH (eds) Hematopoietic cell transplantation. Blackwell Science, Malden, MA, pp 48–57Google Scholar
  129. Micallef IN, Lillington DM, Apostolidis J et al. (2000) Therapy-related myelodysplasia and secondary acute myelogenous leukemia after high-dose therapy with autologous hematopoietic progenitor-cell support for lymphoid malignancies.J Clin Oncol 18: 947–955Google Scholar
  130. Molineux G, McCrea C,Yan XQ, Kerzic P,McNiece I (1997) Flt-3 ligand synergizes with granulocyte colony-stimulating factor to increase neutrophil numbers and to mobilize peripheral blood stem cells with long-term repopulating potential. Blood 89: 3998–4004PubMedGoogle Scholar
  131. Morton J, Hutchins C, Durrant S (2001) Granulocyte-colony-stimulating factor (G-CSF)-primed allogeneic bone marrow: significantly less graft-versus-host disease and comparable engraftment to G-CSF-mobilized peripheral blood stem cells. Blood 98: 3186–3191PubMedGoogle Scholar
  132. Murata M, Harada M, Kato S et al. (1999) Peripheral blood stem cell mobilization and apheresis:analysis of adverse events in 94 normal donors. Bone Marrow Transplant 24: 1065–1071PubMedGoogle Scholar
  133. Murphy WJ, Blazar BR (1999) New strategies for preventing graft-versushost disease.Curr Opin Immunol 11: 509–515Google Scholar
  134. Nash RA, Antin JH, Karanes C et al. (2000) Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood 96: 2062–2068PubMedGoogle Scholar
  135. Orlic D, Kajstura J, Chimenti S et al. (2001) Bone marrow cells regenerate infarcted myocardium. Nature 410: 701–705PubMedGoogle Scholar
  136. Ottinger D, Muller R, Goldmann F et al. (2001) Second German consensus on immunogenetic donor search for allotransplantation of hematopoietic stem cells. Ann Hematol 80: 706–714PubMedGoogle Scholar
  137. Papadopoulos KP, Noguera-Irizarry W, Hesdorffer CS (2001) Tandem trans- plantation in lymphoma. Bone Marrow Transplant 28: 529–535PubMedGoogle Scholar
  138. Pedersen-Bjergaard J, Andersen MK,Christiansen DH (2000)Therapy-related acute myeloid leukemia and myelodysplasia after high-dose chemotherapy and autologous stem cell transplantation. Blood 95: 3273–3279Google Scholar
  139. Peggs KS,Mackinnon S (2001) Cellulartherapy:donor lymphocyte infusion. Curr Opin Hematol 8: 349–354Google Scholar
  140. Petersdorf EW, Gooley TA, Anasetti C et al. (1998) Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and Il alleles in the donor and recipient. Blood 92: 35153520Google Scholar
  141. Petersen BE, Bowen WC, Patrene KD et al. (1999) Bone marrow as a potential source of hepatic oval cells. Science 284: 1168–1170PubMedGoogle Scholar
  142. Petzer AL, Hogge DE, Landsdorp PM, Reid DS, Eaves CJ (1996) Self-renewal of primitive human hematopoietic cells (long-term-culture-initiating cells) in vitro and their expansion in defined medium. Proc Natl Acad Sci USA 93: 1470–1474PubMedGoogle Scholar
  143. Philip T, Guglielmi C, Hagenbeek A et al. (1995) Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med 333: 15401545Google Scholar
  144. Platzbecker U,Thiede C, Freiberg-Richter J et al. (2001) Treatment of relapsing leukemia after allogeneic blood stem cell transplantation by using dose-reduced conditioning followed by donor blood stem cells and GM-CSF. Ann Hematol 80: 144–149Google Scholar
  145. Przepiorka D, Anderlini P, Nasr F (1999) Delayed administration of filgastrim does not abrogate its effect on hematopoietic recovery after HLA-identical blood stem cell transplantation. Blood 94: 151Google Scholar
  146. Przepiorka D, Anderlini P, Saliba R et al. (2001 a) Chronic graft-versus-host disease after allogeneic blood stem cell transplantation. Blood 98: 1695–1700Google Scholar
  147. Przepiorka D, Smith TL, Folloder J et al. (2001 b) Controlled trial of filgrastim for acceleration of neutrophil recovery after allogeneic blood stem cell transplantation from human leukocyte antigen-matched related donors. Blood 97: 3405–3410Google Scholar
  148. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, Thomas ED (1995) 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 15: 825–828Google Scholar
  149. Ratanatharathorn V, Ayash L, Lazarus HM, Fu J, Uberti JP (2001) Chronic graft-versus-host disease: clinical manifestation and therapy. Bone Marrow Transplant 28: 121–129PubMedGoogle Scholar
  150. Ratanatharathorn V, Nash RA, Przepiorka D et al. (1998) Phase Ill study comparing methotrexate and tacrolimus (Prograf,FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood 92: 23032314Google Scholar
  151. Reiser M,Josting A, Draube A et al. (1999) Successful peripheral blood stem cell mobilization with etoposide (VP-16) in patients with relapsed or resistant lymphoma who failed cyclophosphamide mobilization. Bone Marrow Transplant 23: 1223–1228Google Scholar
  152. Richman CM,Weiner RS,Yankee RA (1976) Increase in circulating stem cells following chemotherapy in man. Blood 47: 1031–1039Google Scholar
  153. Richtlinie der Kommission zur Festlegung der Grundsätze and Leitlinien der Guten Herstellungspraxis (GMP) für zur Anwendung beim Menschen bestimmte Arzneimittel (91/356/EWG) vom 13.06.1991Google Scholar
  154. Rocha V, Wagner JE Jr, Sobocinski KA, Klein JP, Zhang MJ, Horowitz MM, Gluckman E (2000) Graft-versus-host disease in children who have received a cord-blood or bone marrow transplant from an HLA-identical sibling. Eurocord and International Bone Marrow Transplant Registry Working Committee on Alternative Donor and Stem Cell Sources. N Engl J Med 342: 1846–1854Google Scholar
  155. Ross AA, Cooper BW, Lazarus HM et al. (1993) Detection and viability of tumor cells in peripheral blood stem cell collections from breast cancer patients using immunocytochemical and clonogenic assay techniques. Blood 82: 2605–2610PubMedGoogle Scholar
  156. Roy V, Rizvi MA, Vesely SK, George JN (2001) Thrombotic thrombocytopenic purpura-like syndromes following bone marrow transplantation:an analysis of associated conditions and clinical outcomes. Bone Marrow Transplant 27: 641–646PubMedGoogle Scholar
  157. Schmitz N, Linch DC, Dreger P et al. (1996) Randomised trial of fiigrastimmobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet 347: 353–357PubMedGoogle Scholar
  158. Schnell R,Hiddemann W, Diehl V,Engert A (2001) Clinical use of monoclon- al antibodies in malignant lymphomas. Internist (Berl) 42: 819–826Google Scholar
  159. Seber A, Shu XO, Defor T, Sencer S, Ramsay N (1999) Risk factors for severe hemorrhagic cystitis following BMT. Bone Marrow Transplant 23: 35–40PubMedGoogle Scholar
  160. Shipp MA, Abeloff MD, Antman KH et al. (1999) International Consensus Conference on High-Dose Therapy with Hematopoietic Stem Cell Transplantation in Aggressive Non-Hodgkin’s Lymphomas: report of thejury.J Clin Oncol 17: 423–429Google Scholar
  161. Shipp MA, Ross KN,Tamayo Petal. (2002) Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 8: 68–74Google Scholar
  162. Shpall EJ,Wheeler CA,Turner SA et al. (1999) A randomized phase 3 study of peripheral blood progenitor cell mobilization with stem cell factor and filgrastim in high-risk breast cancer patients. Blood 93: 24912501Google Scholar
  163. Sica S,Chiusolo P, Salutari P et al. (2000) Autologous graft-versus-host disease after CD34+-purified autologous peripheral blood progenitor cell transplantation.J Hematother Stem Cell Res 9: 375–379Google Scholar
  164. Siegel DS, Desikan KR, Mehta J et al. (1999) Age is not a prognostic variable with autotransplants for multiple myeloma. Blood 93: 51–54PubMedGoogle Scholar
  165. Siena S, Bregni M, Brando B, Ravagnani F, Bonadonna G, Gianni AM (1989) Circulation of CD34+ hematopoietic stem cells in the peripheral blood of high-dose cyclophosphamide-treated patients: enhancement by intravenous recombinant human granulocyte-macrophage colony-stimulating factor. Blood 74: 1905–1914PubMedGoogle Scholar
  166. Siena S,Schiavo R, Pedrazzoli P, Carlo-Stella C (2000) Therapeutic relevance of CD34 cell dose in blood cell transplantation for cancer therapy.J Clin Oncol 18: 1360–1377Google Scholar
  167. Singhal S, Mehta J (1999) Reimmunization after blood or marrow stem cell transplantation. Bone Marrow Transplant 23: 637–646PubMedGoogle Scholar
  168. Singhal S, Powles R,Treleaven J et al. (2000) A low CD34+ cell dose results in higher mortality and poorer survival after blood or marrow stem cell transplantation from HLA-identical siblings: should 2–106 CD34+ cells/kg be considered the minimum threshold? Bone Marrow Transplant 26: 489–496PubMedGoogle Scholar
  169. Slavin S, Nagler A, Naparstek E et al. (1998) Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 91: 756–763PubMedGoogle Scholar
  170. Slovak ML, Kopecky KJ,Cassileth PA et aí. (2000) Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia:a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 96: 4075–4083Google Scholar
  171. Socie G, Clift RA, Blaise D et al. (2001) Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia:long-term follow-up of 4 randomized studies. Blood 98: 3569–3574PubMedGoogle Scholar
  172. Socie G, Curtis RE, Deeg Hi et al. (2000) New malignant diseases after allogeneic marrow transplantation for childhood acute leukemia. J Clin Oncol 18: 348–357PubMedGoogle Scholar
  173. Socinski MA, Cannistra SA, Elias A, Antman KH, Schnipper L, Griffin JD (1988) Granulocyte-macrophage colony stimulating factor expands the circulating haemopoietic progenitor cell compartment in man. Lancet l: 1194–1198Google Scholar
  174. Stevenson FK, Zhu D, Rice J (2001) New strategies for vaccination and immunomodulation in NHL. Ann Hematol 80: B132–134PubMedGoogle Scholar
  175. Stewart AK,Vescio R, Schiller G et al. (2001) Purging of autologous peripheral-blood stem cells using CD34 selection does not improve overall or progression-free survival after high-dose chemotherapy for multiple myeloma: results of a multicenter randomized controlled trial. J Clin Oncol 19: 3771–3779Google Scholar
  176. Stiff P, Chen B, Franklin W et al. (2000a) Autologous transplantation of ex vivo expanded bone marrow cells grown from small aliquots after high-dose chemotherapy for breast cancer. Blood 95: 2169–2174PubMedGoogle Scholar
  177. Stiff P,Gingrich R,LugerS etal. (2000b) A randomized phase 2 study of PBPC mobilization by stem cell factor and filgrastim in heavily pretreated patients with Hodgkin’s disease or non-Hodgkin’s lymphoma. Bone Marrow Transplant 26: 471–481Google Scholar
  178. Storb R, Yu C, Wagner IL et al. (1997) Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood 89: 3048–3054PubMedGoogle Scholar
  179. Storb RF,Champlin R, Ridell SR, Murata M, Bryant S, Warren EH (2001) Nonmyeloablative transplants for malignant disease. Hematology (Am Soc Hematol Educ Program): 375–391Google Scholar
  180. Storek J, Dawson MA, Storer B et al. (2001) Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantation. Blood 97: 3380–3389PubMedGoogle Scholar
  181. Sutherland DR, Anderson L, Keeney M, Nayar R, Chin-Yee I (1996) The ISHAGE guidelines for CD34+ cell determination by flow cytometry. International Society of Hematotherapy and Graft Engineering. J Hematother 5: 213–226Google Scholar
  182. Sutherland HJ, Eaves CJ, Eaves AC, Dragowska W, Lansdorp PM (1989) Characterization and partial purification of human marrow cells capable of initiating long-term hematopoiesis in vitro. Blood 74: 1563–1570PubMedGoogle Scholar
  183. Sweetenham JW, Santini G,Qian Wet al. (2001) High-dose therapy and autologous stem-cell transplantation versus conventional-dose consolidation/maintenance therapy as postremission therapy for adult pa- tients with lymphoblastic lymphoma: results of a randomized trial of the European Group for Blood and Marrow Transplantation and the United Kingdom Lymphoma Group.J Clin Oncol 19: 2927–2936Google Scholar
  184. Thomas ED, Lochte HL, Lu WC, Ferrebee JW (1957) Intravenous infusion of bone marrow in patients receiving radiation and chemotherapy. N Engl J Med 257: 491–496PubMedGoogle Scholar
  185. Thomas ED, Lochte HLJ, Cannon JH, Sahler OD, Ferrebee JW (1959) Supralethal whole body irradiation and isologous marrow transplantation in man.J Clin Invest 38: 1709–1716Google Scholar
  186. To LB, Haylock DN, Kimber RJ, Juttner CA (1984) High levels of circulating haemopoietic stem cells in very early remission from acute non-lymphoblastic leukaemia and their collection and cryopreservation. Br J Haematol 58: 399–410PubMedGoogle Scholar
  187. Tricot G, Alberts DS, Johnson C et al. (1996) Safety of autotransplants with high-dose melphalan in renal failure: a pharmacokinetic and toxicity study.Clin Cancer Res 2: 947–952Google Scholar
  188. Tricot G, Gazitt Y, Leemhuis T et al. (1998) Collection, tumor contamination, and engraftment kinetics of highly purified hematopoietic progenitor cells to support high dose therapy in multiple myeloma. Blood 91: 4489–4495PubMedGoogle Scholar
  189. Tseng LH, Lin MT, Hansen JA et al. (1999) Correlation between disparity for the minor histocompatibility antigen HA-1 and the development of acute graft-versus-host disease after allogeneic marrow transplantation. Blood 94: 2911–2914PubMedGoogle Scholar
  190. Urbano-Ispizua A, Schmitz N, de Witte T, Frassoni F, Rosti G, Schrezenmeier H (2002) Allogeneic and autologous transplantation for haematological diseases, solid tumours, and immune disorders: definitions and current practice Europe. Bone Marrow Transplantation 29: 639–646PubMedGoogle Scholar
  191. van der Wall E, Horn T, Bright E et al. (2000) Autologous graft-versus-host disease induction in advanced breast cancer: role of peripheral blood progenitor cells. BrJ Cancer 83: 1405–1411Google Scholar
  192. Van Zant G (1998) Collection and processing of stem cells. In: Deeg HJ, Klingemann HG, Phillips GL, Van Zant G (eds) A guide to blood and bone marrow transplantation. Springer, Berlin Heidelberg New York, pp 69–79Google Scholar
  193. Vela-Ojeda J,Tripp-Villanueva F, Montiel-Cervantes L et al. (2000) Prospective randomized clinical trial comparing high-dose ifosfamide + GMCSF vs. high-dose cyclophosphamide + GM-CSF for blood progenitor cell mobilization. Bone Marrow Transplant 25: 1141–1146Google Scholar
  194. Verma A, Stock W (2001) Management of adult acute lymphoblastic leukemia: moving toward a risk-adapted approach. Curr Opin Oncol 13: 14–20PubMedGoogle Scholar
  195. Vogelsang GB (2001) How I treat chronic graft-versus-host disease. Blood 97: 1196–1201PubMedGoogle Scholar
  196. Vogelsang GB,Arai S (2001) Mycophenolate mofetil for the prevention and treatment of graft-versus-host disease following stem cell transplantation: preliminary findings. Bone Marrow Transplant 27: 1255–1262Google Scholar
  197. Watts MJ, Sullivan AM,Jamieson E et al. (1997) Progenitor-cell mobilization after low-dose cyclophosphamide and granulocyte colony-stimulating factor:an analysis of progenitor-cell quantity and quality and factors predicting for these parameters in 101 pretreated patients with malignant lymphoma.J Clin Oncol 15: 535–546Google Scholar
  198. Watts MJ, Sullivan AM, Leverett D et al. (1998) Back-up bone marrow is frequently ineffective in patients with poor peripheral-blood stem-cell mobilization.J Clin Oncol 16: 1554–1560Google Scholar
  199. Weaver A, Chang J, Wrigley E et al. (1998) Randomized comparison of progenitor-cell mobilization using chemotherapy, stem-cell factor, and filgrastim or chemotherapy plus filgrastim alone in patients with ovarian cancer.) Clin Oncol 16: 2601–2612Google Scholar
  200. Weaver CH, Hazelton B, Birch R, Palmer P, Allen C, Schwartzberg L, West W (1995) An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood 86: 3961–3969PubMedGoogle Scholar
  201. Weaver CH, Schulman KA, Wilson-Relyea B, Birch R, West W, Buckner CD (2000) Randomized trial of filgrastim, sargramostim, or sequential sar-gramostim and filgrastim after myelosuppressive chemotherapy for the harvesting of peripheral-blood stem cells.J Clin Oncol 18: 43–53PubMedGoogle Scholar
  202. Weaver CH, Schwartzberg LS, Birch R et al. (1997) Collection of peripheral blood progenitor cells after the administration of cyclophosphamide, etoposide, and granulocyte-colony-stimulating factor: an analysis of 497 patients.Transfusion 37: 896–903Google Scholar
  203. Weiden PL, Sullivan KM, Flournoy N, Storb R, Thomas ED (1981) Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. N Engl J Med 304: 1529–1533PubMedGoogle Scholar
  204. Weissman IL (2000a) Stem cells: units of development, units of regeneration, and units in evolution.Cell 100: 157–168Google Scholar
  205. Weissman IL (2000b) Translating stem and progenitor cell biology to the clinic: barriers and opportunities. Science 287: 1442–1446PubMedGoogle Scholar
  206. Wiesmann A, Pereira P, Bohm P, Faul C, Kanz L, Einsele H (1998) Avascular necrosis of bone following allogeneic stem cell transplantation: MR screening and therapeutic options. Bone Marrow Transplant 22: 565–569Google Scholar
  207. Williams CD, Harrison CN, Lister TA et al. (2001) High-dose therapy and autologous stem-cell support for chemosensitive transformed low-grade follicular non-Hodgkin’s lymphoma: a case-matched study from the European Bone Marrow Transplant Registry.J Clin Oncol 19: 727–735Google Scholar
  208. Winter JN, Lazarus HM, Rademaker A et al. (1996) Phase I/II study of combined granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor administration for the mobilization of hematopoietic progenitor cells. J Clin Oncol 14: 277–286PubMedGoogle Scholar
  209. Wissenschaftlicher Beirat der Bundesärztekammer (1994) Richtlinien für die allogene Knochenmarktransplantation mit nichtverwandten Spendern. Dt Ärztebl 11: B 578–582Google Scholar
  210. Wissenschaftlicher Beirat der Bundesärztekammer (1997) Richtlinien zur Transplantation peripherer Blutstammzellen. Dt Ärztebl 94: A 15841592Google Scholar
  211. Wissenschaftlicher Beirat der Bundesärztekammer (1999) Richtlinien zur Transplantation von Stammzellen aus Nabelschnurblut (CB = Cord Blood). Dt Ärztebl 96:A 1297–1304Google Scholar
  212. Wissenschaftlicher Beirat der Bundesärztekammer (2000) Richtlinien zur Gewinnung von Blut und Blutbestandteilen und zur Anwendung von Blutprodukten (Hämotherapie). Bundesgesundheitsbl–Gesundheitsforsch–Gesundheitsschutz 43: 555–589Google Scholar
  213. Witherspoon RP, Fisher LD, Schoch G et al. (1989) Secondary cancers after bone marrow transplantation for leukemia or aplastic anemia. N Engl J Med 321: 784–789PubMedGoogle Scholar
  214. Yin AH,Miraglia S,Zanjani ED et aí. (1997) AC133,a novel marker for human hematopoietic stem and progenitor cells. Blood 90: 5002–5012Google Scholar
  215. Zaucha JM, GooleyT, Bensinger WI et al. (2001) CD34 cell dose in granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell grafts affects engraftment kinetics and development of extensive chronic graft-versus-host disease after human leukocyte antigen-identical sibling transplantation. Blood 98: 3221–3227PubMedGoogle Scholar
  216. Zeller W, Gutensohn K, Stockschlader M et al. (1996) Increase of mobilized CD34-positive peripheral blood progenitor cells in patients with Hodgkin’s disease, non-Hodgkin’s lymphoma,and cancer of the testis. Bone Marrow Transplant 17: 709–713PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2004

Authors and Affiliations

  • C. Scheffold
  • W. E. Berdel
  • J. Kienast

There are no affiliations available

Personalised recommendations